Adverse events: all grades · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2
Tixagevimab/cilgavimab showed no clear difference in adverse events: all grade within 6 monthsb compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Intervention not reported
Any adverse events during the trial period · people with moderate to severe disease (WHO scale 4–9); all trials contributing results to the summary of findings table investigated…
The intervention showed no clear difference in any adverse events during the trial period (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · children with chronic asthma
Children: formoterol/fluticasone showed no clear difference in all‐cause non‐fatal serious adverse events compared with salmeterol/fluticasone (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse event: lead failure/ displacement · adults with chronic pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events during treatment period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Adverse events during treatment period · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in any adverse events during the study period compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Adverse events: serum calcium above normal · relatively healthy postmenopausal women
Vitamin D plus calcium showed no clear difference in adverse events: serum calcium above normal compared with placebo (low certainty).
1 finding from 1 review
Proportion of children with adverse events · children with nocturnal enuresis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of children with adverse events · children with nocturnal enuresis
Alarm probably leads to lower proportion of children with adverse events compared with desmopressin (moderate certainty).
1 finding from 1 review
Proportion of children with adverse events · children with nocturnal enuresis
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Proportion of children with adverse events · children with nocturnal enuresis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of children with adverse events · children with nocturnal enuresis
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Proportion of children with adverse events · children with nocturnal enuresis
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have had long‐term red cell transfusions to prevent a stroke
1 finding from 1 review
Adverse events associated with transfusion · individuals with sickle cell disease who are at risk of a primary stroke who have not had previous long‐term red cell transfusions
It is very uncertain whether long‐term red cell transfusion changes adverse events associated with transfusion compared with no transfusion (very low certainty).
1 finding from 1 review
Pneumonia and other serious adverse events · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Incidence of adverse events at 3 months of · people with meibomian gland dysfunction
1 finding from 1 review
no estimate extracted
Studies not reported
Very low